Migraine treatment took a leap forward with CGRP inhibitors, a drug class that has progressed from novel medicines to first-line therapies over the past decade. But there’s still an unmet need for patients who don’t respond to these and other migraine treatments. Startup Slate Medicines raised $130 million to start clinical tests of a novel drug that could give patients a new choice.CGRP-blocking drugs were based on research showing the role that the target protein plays in migraine progression....
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.
Alternative Investment News